Artixio

Biologics Product Registration & Regulatory Services in South Korea

Ensuring Regulatory Compliance for Biologics, From Strategy to Registration and Post Approval Maintenance. Our team supports full regulatory planning for biologics product registration in South Korea, ensuring compliance with MFDS standards and smooth market access.

Artixio’s Services in South Korea for Biologics

South Korea is a global hub for biologics and biosimilars. The Korean pharmaceutical market is estimated to be $1.16 billion by 2027 & CAGR of 21.6%. Artixio offers end-to-end regulatory services to global manufacturers, facilitating smooth approval with strong understanding of international regulatory frameworks and provide strategic, efficient, and market-ready pathways for biologics entering the South Korean market.

Classification of Biologics in South Korea

South Korea Regulatory Support for Biologics Product Approval

From Development to Product Lifecycle Management

Pre-Registration

Registration

Post Market Maintenance

Process for Registration of Biologics in South Korea

The Ministry of Food and Drug Safety (MFDS) is the Regulatory body regulates the Biologics in South Korea. Biologics License Applications (BLAs) must adhere to the format outlined by the Ministry of Food and Drug Safety (MFDS), often following the Electronic Common Technical Document (eCTD) structure.

Why Artixio For Biologics Compliance & Product Registration with MFDS?

Strong Regulatory Insights from our regulatory specialists.
End-to-End Support: From conceptualization to post-market compliance
120+ Countries with Expert Regional Regulatory Teams
Ensure ................. biologics/ biosimilar product licence compliance
Industry Recognized (CPHI Pharma Awards 2024) Tech-Enabled, Regulatory Intelligence driven Services
Responsive, collaborative regulatory services.
ISO 9001:2015, Quality Driven Services Platform
Customer Focused, Nimble Team
KPI based, continual process excellence

FAQs

What is South Korea’s New Regulatory Data Protection System?
The new regulatory data protection system in South Korea grants data exclusivity to Marketing Authorization applications filed from 21st Feb 2025. Application filed before 21st Feb 2025 follow under old Re-examination system.
Data protection period is same for both Biologics and Drug. New Biological Entity- 6 years from date of Marketing approval (MA) Orphan Product – 10 years from date of MA Paediatric Use – Add on 1 year to existing exclusivity.
For Standard application pathway, after submission of Biologics License Application (BLA) MFDS will take 115-180 days for review and decision by MFDS.
Applicant must submit application to Health authority as electronic documents through KiFDA online system.
Foreign manufacturers require South Korean business entity with valid manufacturing license to register product. Applications for consultation or submission can be prepared and submitted to MFDS through the Local representatives. At Artixio, we also provide Local Representative services to expedite product registration and regulatory compliance in South Korea.

Regulatory Expertise Across Multiple Countries

India
Vietnam
Mexico​
Vietnam
United States
Brazil
Europe
Malaysia
Taiwan
China
Thailand
Philippines

Industries we serve

Pharmaceuticals

Cosmetics

Nutrition

Medtech

Biologics

Veterinary

Blogs

CDSCO Medical Device Approval Cost & Fee Structure

CDSCO Medical Device Approval

Central Drug Standard Control Organization (CDSCO) is the regulatory authority that regulates Medical Devices...

July 29, 2025
Computer Software Assurance(CSA) In Pharma & Medical Industry

Computer Software Assurance(CSA) In

Under 21 CFR part 11, it is required to validate the electronic systems that...

July 28, 2025
In Vitro Diagnostics: Meaning, Types And Benefits

In Vitro Diagnostics: Meaning,

The term “in vitro” is a Latin word that means “in glass”. Thus, from...

June 20, 2025